Effects of a-tocopherol on hemolysis and oxidative stress markers on red blood cells in ß-thalassemia major

a:5:{i:0;s:423:"Background: The accumulation of unpaired alpha-globin chains in patients with ss-thalassemia major may clinically create ineffective erythropoiesis, hemolysis, and chronic anemia. Multiple blood transfusions and iron overload cause cellular oxidative damage. However, alpha-tocopherol, an antioxidant, is a potent scavenger of lipid radicals in the membranes of red blood cells (RBCs) of patients with ss-thalassemia major.";i:1;s:154:"Purpose: To evaluate the effects of alpha-tocopherol on hemolysis and oxidative stress markers on the RBC membranes of patients with ss-thalassemia major.";i:2;s:460:"Methods: Forty subjects included in this randomized controlled trial were allocated to the placebo and alpha-tocopherol groups. Doses of alpha-tocopherol were based on Institute of Medicine recommendations: 4-8 years old, 200 mg/day; 9-13 years old, 400 mg/day; 14-18 years old, 600 mg/day. Hemolysis, oxidative stress, and antioxidant variables were evaluated before and after 4-week alpha-tocopherol or placebo treatment, performed before blood transfusions.";i:3;s:344:"Results: Significant enhancements in plasma haptoglobin were noted in the a-tocopherol group (3.01 mg/dL; range, 0.60-42.42 mg/dL; P=0.021). However, there was no significant intergroup difference in osmotic fragility test results; hemopexin, malondialdehyde, reduced glutathione (GSH), or oxidized glutathione (GSSG) levels; or GSH/GSSG ratio.";i:4;s:214:"Conclusion: Use of alpha-tocopherol could indirectly improve hemolysis and haptoglobin levels. However, it played no significant role in oxidative stress or as an endogen antioxidant marker in ss-thalassemia major.";}